Berenson addressed the competitive landscape primarily in the context of wearable devices such as WHOOP, which the interviewer raised as a potential substitute. Berenson argued that wearables fail with the chronic and elderly patient population because compliance is the central problem: charging, wearing, pairing with a phone, and tolerating the device all create friction that leads to low adherence. He did not cite specific revenue or customer figures for any wearable competitor, and no competitor figures should be taken as company-confirmed data.
Berenson identified Medtronic, Masimo, ResMed, and Philips as leading medical device companies he would consider strategic investors, implying they operate in adjacent monitoring markets. He did not characterize them as direct competitors.